Good News for Market-Leading Stent

A new study by Abbott Laboratories found that their drug-coated stent, Xience V, is more effective in the long term than a competitor’s. According to the Wall Street Journal, the data showed that rates of major cardiovascular events plateaued at 6.4% in the second and third years after Xience was implanted.

Read more »